![](https://medcitynews.com/wp-content/uploads/sites/7/2018/05/GettyImages-635475308.jpg)
AstraZeneca reports promising lung cancer results from Phase III immunotherapy drug trial
The company said Imfinzi and chemotherapy, with or without tremelimumab, extended progression-free survival in first-line non-small cell lung cancer versus chemotherapy, setting up Imfinzi as a potential competitor to Merck's Keytruda. Overall survival data are expected next year.